Pfizer Inc. reported a strong first quarter in 2024, with adjusted earnings per share (EPS) of $0.82, surpassing estimates of around $0.52 to $0.54. The company's revenue reached $14.9 billion, exceeding forecasts that ranged from $13.91 billion to $14.2 billion, despite a 20% decline year-over-year. Notably, Pfizer's COVID-19 antiviral treatment, Paxlovid, generated revenues of $2.04 billion, while its COVID-19 vaccine, Comirnaty, brought in $345 million, below the expected $591.6 million. The company has raised its full-year revenue forecast to between $58.5 billion and $61.5 billion and adjusted its EPS forecast to $2.15 to $2.35, up from the previous range of $2.05 to $2.25. Pfizer also highlighted that no share repurchases are planned for 2024, attributing part of its financial success to cost cuts and strong non-COVID product sales.